FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* White Marvin L					2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [APVO]					(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
	(Last) (First) (Middle) C/O APTEVO THERAPEUTICS INC. 2401 4TH AVENUE, SUITE 1050						3. Date of Earliest Transaction (Month/Day/Year) 01/29/2021					X Officer (give title below) President and CEO					
(Street) SEATTL (City)			98121 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							i. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non-D	erivativ	re Se	curities	s Ac	quired, Di	sposed o	of, or Bei	neficiall	y Owned					
Date			Transactio te onth/Day/\	2A. Deemed Execution Date,			3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4					s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	4. Trans Code	4. Transaction Code (Instr.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly Do (I	0. Iwnership orm: Virect (D) r Indirect) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$33.5	01/29/2021		A		43,125		(1)	01/29/2031	Common Stock	43,125	\$0	43,125	5	D		
Restricted Stock Unit	(2)	01/29/2021		A		14,375		(3)	(3)	Common Stock	14,375	\$0	14,375	5	D		

- $1. \ The \ option \ vests \ in \ three \ approximately \ equal \ annual \ installments \ beginning \ on \ January \ 29, \ 2022.$
- 2. Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.
- 3. The RSU vests in three approximately equal annual installments beginning on January 29, 2022.

/s/ Carl A. Valenstein, attorney-02/17/2021 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.